Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic, Biosense tackle arrhythmias

This article was originally published in Clinica

Executive Summary

Medtech giant Medtronic and Johnson & Johnson subsidiary Biosense Webster are to collaborate on exploring new technologies for better diagnosing and treating patients with cardiac arrhythmias. The companies said they intend to combine Biosense's know-how in cardiac imaging and navigation with Medtronic's expertise in cardiac monitoring and diagnostics to create a new care protocol for identifying patients most likely to have a successful ablation treatment. The firms will also integrate their respective technologies to develop new therapies for complex cardiac arrhythmias under a joint R&D programme.

You may also be interested in...



P&G's $8M Benzene Settlement Preliminarily Approved By Ohio Federal Court

The Cincinnati, OH-based firm will pay $8m to recompense Unites States residents who purchased aerosol personal-care products potentially contaminated with benzene over a roughly six-year period.

Food For Thought On US FDA Reforms

An independent review of the US FDA’s food regulatory programs could renew a debate over splitting FDA into two agencies. That could be a distraction for the agency in the coming year – but it could also help keep the medical product review groups out of the political hot seat.

FDA’s Win-Win: More Comprehensive IND Safety Reports With Minimal Effort Due To Harmonization

New proposed rule calls for replacing US FDA’s current annual reporting requirements for INDs with a safety update report that is consistent the format and content of the development safety update report (DSUR) supported by the International Council of Harmonisiation.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT048339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel